This trial is active, not recruiting.

Condition type 2 diabetes
Treatment treatment algorithms
Phase phase 4
Sponsor University of Pittsburgh
Collaborator American Diabetes Association
Start date April 2012
End date December 2015
Trial size 370 participants
Trial identifier NCT01611168, PRO08040023


The proposed research study aims to determine whether applying the University of Pittsburgh Medical Center Nurse-Directed Diabetes Management Protocols (NDMPs) leads to improved clinical outcome and process measures as recommended by American Diabetes Association (ADA), quality of life, treatment satisfaction and medication adherence for adults with diabetes, and favorable providers' satisfaction as compared to usual diabetes care. Furthermore, the cost-effectiveness of performing the NDMPs compared to usual diabetes care in primary care settings will also be assessed.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
(No Intervention)
treatment algorithms
subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.

Primary Outcomes

Glycated hemoglobin (A1C)
time frame: 1 year
Blood pressure (systolic and diastolic blood pressure
time frame: 1 year
Lipids (LDLc, HDLc, cholesterol, and triglyceride)
time frame: 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Adults aged 18 or greater 2. The diagnosis of type 2 diabetes of the subjects should be 1 year or more prior to the inception of this study 3. Subjects will be on medication treatment for their type 2 diabetes 4. Subjects' A1C levels should be higher than 7% for study entry 5. LDLc>100mg/d*l or 6. Blood Pressure >130/80*mg/dl 7. Any combination of the #4, 5 &6 At least one visit to the practice within the previous 12 months. Exclusion Criteria: 1. Non-ambulatory 2. Gestational diabetes 3. Pregnant women (by self-report) 4. Subjects have received diabetes education services performed by the registered nurse from UPDI 5. Subjects are treated with exercise and diet only 6. Subjects are participating or will participate in other research studies 7. Subjects do not have insurance or cannot afford payments for diabetes care/treatment 8. Subjects are unable to read and comprehend English 9. Subjects are unable to provide informed consent 10. Other medical conditions for which these protocols are deemed inappropriate by the physician.

Additional Information

Official title Redesigning Medication Intensification Effectiveness Study for Diabetes
Principal investigator Janice Zgibor, RPh PhD
Description This proposed study is a multi-practice, cluster-design, prospective randomized controlled trial with a total study intervention period of 12 months. This prospective randomized controlled trial will assess the effectiveness of performing NDMPs by the registered nurse supervised by a physician (the intervention group) in comparison with usual diabetes care (the usual care group) for adults with diabetes in primary care settings. The study population will be recruited from University of Pittsburgh Medical Center Community Medicine Inc. (CMI) primary care practices in urban and suburban communities surrounding Pittsburgh, PA. Among these CMI practices, ten practices receive diabetes education services from University of Pittsburgh Diabetes Institute and will be the intervention group. These diabetes education services will be enhanced by the addition of NDMPs intervention. In addition, we will select another 10 CMI practices to be the usual care group. This group receives standard diabetes education with no use of NDMPs. One-hundred and fifty participants will be recruited across practices within each study group (i.e., 300 in total). Outcomes assessed in this study include clinical outcome and process measures as recommended by ADA, participants' quality of life, treatment satisfaction, and medication adherence, and providers' satisfaction, and costs/expenditure. Assessments will be done at baseline, and three and 12 months after the study entry. Analysis of the study outcomes will be based on intention-to-treat to determine (1) within-group differences between the baseline and follow-up visits, and (2) between-group differences between the intervention group and the usual care group.
Trial information was received from ClinicalTrials.gov and was last updated in December 2014.
Information provided to ClinicalTrials.gov by University of Pittsburgh.